Figure 1.

Competitive inhibition by TRAIL death receptors for rhTRAIL^WT and variants 4C7 and 4C9, binding to immobilized DR4-Ig, using soluble DR4-Ig as a competitor (a) and soluble DR5-Ig as a competitor (b), in the presence of 100 ng/ml of rhTRAIL^WT or variants and 0–5000 ng/ml per well of DR4- or DR5-Ig. Binding of rhTRAIL^WT and variants was measured relative to the wells containing no soluble receptor